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Abstract 
Several magnetic resonance techniques have been proposed as non-invasive imaging biomarkers for the evaluation of 
disease progression and early diagnosis of Alzheimer’s Disease (AD). This work is the first application of the Proton 
Magnetic Resonance Spectroscopy 1H-MRS data and machine-learning techniques to the classification of AD. A 
gender-matched cohort of 260 subjects aged between 57 and 99 years from the Alzheimer’s Disease Research Unit, 
of the Fundación CIEN-Fundación Reina Sofía has been used. A single-layer perceptron was found for AD prediction 
with only two spectroscopic voxel volumes (Tvol and CSFvol) in the left hippocampus, with an AUROC value of 
0.866 (with TPR 0.812 and FPR 0.204) in a filter feature selection approach. These results suggest that knowing the 
composition of white and grey matter and cerebrospinal fluid of the spectroscopic voxel is essential in a 1H-MRS 
study to improve the accuracy of the quantifications and classifications, particularly in those studies involving elder 
patients and neurodegenerative diseases. 
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1. Introduction 
Over the past decades, researchers have tried to define this grey area of cognitive decline that 
probably represents a transitional state between usual brain ageing and dementia (Metastasio et al., 2006). 
Mild cognitive impairment (MCI) was proposed as a transitional state between healthy ageing and 
Alzheimer’s Disease (AD) (Grundman et al., 2004). Although MCI is a category at high risk of 
developing dementia, namely 10–15% per year compared to 1–2% in the healthy elderly population (Ackl 
et al., 2005), some MCI patients never develop dementia and not all AD patients pass through MCI stage. 
Many studies were performed in order to detect clinical, neuropsychological and biological predictive 
markers of progression of MCI to AD (Metastasio et al., 2006). Brain damage in AD and MCI begins in 
the medial temporal lobe, including the hippocampus, the parahippocampal gyrus and entorhinal cortex 
extending to the limbic system (Devanand et al., 2007, Hampel et al., 2008, Holland et al., 2009 and Raji 
et al., 2009). Medial temporal lobe and hippocampal atrophy was considered as a significant marker of 
dementia in subjects with mild cognitive impairment (de Leon et al., 1993, Korf et al., 2004 and Visser et 
al., 2002).  
Several structural and functional magnetic resonance (MR) techniques have been proposed as non-
invasive imaging biomarkers for the evaluation of disease progression and early diagnosis of AD. The 
analysis of these biomarkers allows the study of differences between groups (e.g. disease vs. healthy 
groups). However, these methods are not applicable on a single-subject level and therefore do not 
improve the clinical diagnosis potential. In order to overcome this issue, machine-learning techniques 
have recently been identified as promising tools in neuroimaging data analysis for individual class 
prediction. Advances in medical imaging and medical image analysis have provided a means to generate 
and extract valuable neuroimaging information. Automatic classification techniques provide tools to 
analyse this information and observe inherent disease-related patterns in the data. In particular, these 
classifiers have been used to discriminate AD patients from healthy control subjects and to predict 
conversion from MCI to AD. 
MR modalities produce extremely high-dimensional raw data that can contain inherent patterns related 
to AD. Machine-learning methods are helpful tools for analysing many variables simultaneously and 
finding inherent patterns in the neuroimaging data. A wide range of different supervised classifiers has 
been used in the field of AD classification and MCI prediction (Falahati, Westman, & Simmons, 2014). 
Support vector machines (SVM) are commonly used in AD research for multivariate classification 
(Adaszewski et al., 2013, Aguilar et al., 2013, Andrade de Oliveira et al., 2015, Kloppel et al., 2008, Liu 
et al., 2013, Magnin et al., 2009, Plant et al., 2010, Tong et al., 2014, Varol et al., 2012, Vemuri et al., 
2008 and Young et al., 2013). Principal Components Analysis (PCA) (Eskildsen et al., 2013, 
Koikkalainen et al., 2011, Teipel et al., 2007 and Westman et al., 2011) and linear discriminant analysis 
(LDA) (Cho et al., 2012, Coupe et al., 2012, Eskildsen et al., 2013, Liu et al., 2013 and McEvoy et al., 
2011) are well-known statistical classifiers which have been used for AD classification. Among other 
methods, there are artificial neural networks (ANNs) (Aguilar et al., 2013 and Escudero et al., 2011) or 
decision trees (DT) (Aguilar et al., 2013, Hamou et al., 2011 and Querbes et al., 2009). All these works 
are based on anatomical MR imaging (MRI) biomarkers, such as volumetric or cortical thickness 
measures, to help discriminate AD subjects from elderly control or MCI subjects. However, other MR 
techniques, such as Diffusion Tensor Imaging (DTI), have been explored in the automatic classification 
of MCI patients (Dyrba et al., 2013, Haller et al., 2010 and O’Dwyer et al., 2012). The collection of Weka 
machine-learning algorithms (Hall et al., 2009) was also used for the learning and classification processes 
in the detection of microstructural white matter degeneration in AD with DTI (Dyrba et al., 2013) and for 
the detection of brain atrophy patterns based on MRI for the prediction and early detection of AD (Farhan 
et al., 2014 and Plant et al., 2010). Weka is a full toolkit for classification and regression used for several 
other purposes such as the detection of autism (Kosmicki, Sochat, Duda, & Wall, 2015), annotation of 
diverse human tissues (Ernst & Kellis, 2015) or for the classification of cell death-related proteins 
(Fernandez-Lozano, Gestal, et al., 2014). 
Proton Magnetic Resonance Spectroscopy (
1
H-MRS) is a useful technique for studying brain 
metabolites in both health and illness (Frederick et al., 2004, Lin et al., 2005 and Ross and Sachdev, 
2004). The main difference between standard MRI and 
1
H-MRS is that the frequency of the MR signal is 
used to encode different types of information. MRI uses high spatial resolution to generate anatomical 
images, whereas 
1
H-MRS provides chemical information about the tissues. Rather than images, 
1
H-MRS 
data are presented as line spectra where the peaks on the spectra obtained correspond to various 
metabolites, both normal and abnormal, which may be identified accurately. The area under each peak 
represents the relative concentration of nuclei detected for a given chemical species. 
1
H-MRS studies provide insight into the in vivo metabolism of dementia and in particular Alzheimer’s 
Disease, identifying an evolutionary pattern of regional metabolite abnormalities ( Ackl et al., 2005). 
Among various substances assessed using 
1
H-MRS, functional significances in 3 metabolites are of 
interest to the current study and have been discussed at length in the literature reporting on cognitive 
disorders (Watanabe, Shiino, & Akiguchi, 2010): N-acetylaspartate (NAA), myo-inositol (mI) and 
choline compounds (Cho). In AD, the main finding using 
1
H-MRS is the decreased levels of NAA and the 
increased levels of mI in the occipital, temporal, parietal, and frontal regions of patients with AD, even at 
the early stages of the disease ( Miller et al., 1993, Moats et al., 1994, Valenzuela and Sachdev, 
2001 and Waldman and Rai, 2003). NAA is a marker of healthy neuronal density. Consistent with this 
and with the pathological changes known to occur in neurodegenerative dementing illnesses (Pearson, 
Esiri, Hiorns, Wilcock, & Powell, 1985), localised 
1
H-MRS has shown reduced NAA in different brain 
regions of AD and MCI patients ( Ackl et al., 2005, Chantal et al., 2004, Chantal et al., 2002, Falini et al., 
2005, Kantarci et al., 2007, Modrego and Fayed, 2012, Schuff et al., 2002 and Valenzuela and Sachdev, 
2001). mI is primarily located in glial cells and has been interpreted as a marker for glial activation 
(Tumati, Martens, & Aleman, 2013). There have been reports of increased mI, which is suggestive of an 
increase in glial content or membrane abnormality in subjects with AD ( Ernst et al., 1997, Huang et al., 
2001, Kantarci et al., 2000, Parnetti et al., 1997, Shonk et al., 1995 and Siger et al., 2009).  
Despite the fact that machine-learning techniques have been widely used for MRI images in the study 
of AD, there are no studies on their application to 
1
H-MRS data. However, there are several studies that 
use classification methods such as LDA and PCA, for brain tumour classifications with spectroscopic data 
(Davies et al., 2008, Opstad et al., 2007, Raschke et al., 2013 and Raschke et al., 2012). In the study of 
AD, the work carried out by Di Deco et al. (2013) uses combinations of different MR neuroimaging 
biomarkers, including 
1
H-MRS metabolites, in order to find the most accurate biomarkers in diagnosing 
or predicting this pathology in its different phases. 
Among the reasons why there are no machine-learning studies for single-subject level classification 
with 
1
H-MRS in AD may be the increase of 
1
H-MRS variability due to normal ageing and also as a result 
of atrophy in grey and white matter caused by neurodegeneration. 
1
H-MRS techniques use rectangular or 
cubic voxels, which do not usually correspond to the curved shapes of the brain regions. In this regard, 
the spectroscopy voxel often includes a combination of cerebrospinal fluid (CSF), grey matter (GM) and 
white matter (WM). Because CSF has no measurable 
1
H-MRS metabolites, the presence of a large portion 
of CSF within the voxel, as could happen by tissue atrophy in these diseases, could affect the metabolite 
concentrations. 
The aim of this study was to test and evaluate the effectiveness of machine-learning schemes for 
single-subject level classification of individuals affected by different stages of dementia (healthy elderly 
subjects, MCI and AD subjects) based on 
1
H-MRS data. The collection of Weka machine-learning 
algorithms was used for this purpose. To overcome the problem of variations in tissue composition in the 
voxel, the volumes of GM, WM and CSF within the spectroscopic voxel were also used for the analysis. 
2. Materials 
2.1. Subjects 
A gender-matched cohort of 260 subjects aged between 57 and 99 years was used. They were 
submitted to the study in the Alzheimer’s Disease Research Unit, of the Fundación CIEN-Fundación 
Reina Sofía. The approval from the local ethics committee was obtained for this study, and all patients 
gave their informed consent for participation. All participants received the Mini-Mental State 
Examination (MMSE; (Folstein, Folstein, & McHugh, 1975)) and the Clinical Dementia Rating Scale 
(CDR) to assess their cognitive function (Hughes, Berg, Danziger, Coben, & Martin, 1982). The 
diagnostic assessment of the MCI patients was performed according to Petersen’s criteria (Petersen et al., 
1999). The Alzheimer’s Disease status was assigned according to the National Institute of Neurological 
and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association 
(NINCDS/ADRDA; (McKhann et al., 1984)) criteria for AD. These subjects were classified into 4 groups 
according to these criteria: 99 healthy participants (Control, 58 women, 41 men, mean age 71.8 ± 5.8 y), 
49 amnestic Mild Cognitive Impairment patients (aMCI, 27 women, 22 men, mean age 74.5 ± 6.2 y), 45 
multi-domain Mild Cognitive Impairment patients (mMCI, 30 women, 15 men, mean age 75.6 ± 5.2 y) 
and 67 Alzheimer’s Disease patients (AD, 48 women, 19 men, mean age 76.6 ± 6.5 y) in an earlier stage 
of the disease. The Control subjects had an average MMSE score of 28.4 ± 1.9, aMCI patients of 
23.2 ± 0.5, mMCI patients of 23.5 ± 2.5 and AD subjects of 17.4 ± 4.6. The average CDR rate was 
0.11 ± 0.2 for Control subjects, 0.80 ± 0.5 for aMCI subjects, 0.85 ± 0.2 for mMCI subjects and 1.2 ± 0.5 
for AD subjects. 
2.2. Data acquisition and post-processing 
All MR images and spectroscopic data were acquired with a clinical GE Signa HDx 3.0T scanner 
using a single-channel quadrature head coil. The MRI protocol included a spoiled gradient echo (IR-
SPGR) high-resolution T1 volume (TR/TE/TI/flip angle = 9/4/650 ms/12, matrix = 512 × 512, 
FOV = 24 × 24 cm, NEX = 1, 158 slices × 1.0 mm slice thickness). The spectroscopy protocol consisted 
of three Point Resolved Spin-Echo (PRESS) acquisitions with TR = 1500 ms and TE = 35 ms: two single-
voxel spectra (SV) with a mean size of 5.5 cm
3
 were prescribed in both hippocampi, and an SV with a 
mean size of 8 cm
3
 was placed in the parietal lobe. 
Metabolite quantification was performed with the LCModel software (Provencher, 2001) for the 
automatic quantitation of in vivo
1
H-MRS spectra. LCModel method fits experimental data with a so-
called ‘basis set’ of spectra. The basis set is acquired from solutions acting as concentration references for 
the in vivo acquisitions. LCModel defines the concentrations of the pertinent metabolites by scaling the 
relative areas and chemical shifts across the two sets of spectra. The fitting of the spectral peaks was thus 
achieved with a priori knowledge of their actual characteristics. The main brain metabolites, choline 
(Cho), creatine (Cre), N-acetylaspartate (NAA), and myo-inositol (mI) were recorded with this software 
to get their concentrations. The height and area values for each of these peaks were also obtained in the 
spectrum with MATLAB software ( The MathWorks, Inc., 2014) in order to evaluate their potential as 
quantification measures. 
Fig. 1 displays the typical single-voxel spectroscopy prescription in the right hippocampus from one 
subject, registered onto a high-resolution T1-weighted image in the sagittal (a), transverse (b) and coronal 
(c) planes. The resulting spectrum from LCModel software is shown in (d). The spectrum exhibits four 
distinctive peaks, these being (from right to left) NAA, Cr, Cho and mI. 
 
 
 
Fig. 1. Single voxel prescription in the right hippocampus from one subject, registered onto a high-resolution T1 SPGR: sagittal (a), 
transverse (b) and coronal (c) view. Resulting LCModel spectrum (d). 
The high-resolution 3D structural images were segmented into grey matter (GM), white matter (WM) 
and cerebrospinal fluid (CSF) using SPM8 software (SPM, 2014). After this segmentation, the 
composition of GM, WM and CSF for each spectroscopic voxel was calculated by localising the 
1
H-MRS 
voxel onto the three segmented volumes. 
2.3. Dataset and analysis description 
The dataset was divided into the previously described groups (classes): Control, aMCI, mMCI and 
AD. Additional classes were created by combining the original ones: Alz (aMCI, mMCI, AD) and MCI 
(aMCI and mMCI). Moreover, cases from the three different brain locations were analysed: right 
hippocampus (RH), left hippocampus (LH) and parietal lobe (PL). Table 1 describes the number of cases 
for each class by brain region. The number of cases varies by regions because some subjects could not 
complete the spectroscopy protocol. 
Table 1. Number of cases for each class and brain region. 
Class LH RH PL 
    
Control 98 96 99 
aMCI 49 45 49 
mMCI 45 41 36 
AD 67 60 61 
Alz* 161 146 146 
MCI** 94 86 85 
    
 
* Alz = aMCI, mMCI, AD. 
** MCI = aMCI, mMCI. 
  
A total of 20 attributes resulted from the post-processing analysis: mI_Conc, Cho_Conc, Cre_Conc 
and NAA_Conc (LCModel concentrations of the 4 metabolites), mI/Cr, Cho/Cr, NAA/Cr and mI/NAA 
(LCModel ratios), mI_Ampl, Cho_Ampl, Cre_Ampl and NAA_Ampl (Peak amplitudes or heights), 
mI_Area, Cho_Area, Cre_Area and NAA_Area (Peak areas), Tvol (total volume of the spectroscopic 
voxel), GMvol, WMvol and CSFvol (GM, WM and CSF volumes of the spectroscopic voxel, 
respectively). Additional 2 attributes were created as ratios of the volumes: CSFvol/Tvol (CSF volume 
relative to the total volume of the voxel) and GMvol/Tvol (GM volume related to the total volume of the 
voxel). Therefore, each case had finally 22 attributes. For each of the 3 brain regions (LH, RH, PL), 5 
classes (aMCI, mMCI, AD, Alz, MCI) were used vs. Control in order to test 5 types of classification that 
could predict any Alzheimer stage cases vs. healthy cases. 
3. Classification methods 
In order to minimise the influence of bias on the original data during training process, to avoid 
overfitting and to obtain the generalisation error of the model, the different Weka algorithms were applied 
using the well-known 10-fold cross-validation technique to split the data. Cross-validation is a statistical 
method for evaluating and comparing classifiers. The idea behind it is to use a part of the dataset to train 
the classifier, and thereafter use the remaining samples, as a new and unseen set, to test the performance 
of the classifier. In the 10-fold cross-validation, samples are divided into 10 folds and subsequently 10 
iterations of training and validation are performed, so that each fold is used once and only once for 
validation. Thus, for each round of cross-validation, the performance of the model can be calculated 
separately, which decreases the variance of the evaluation. 
The performance of prediction models for a two-class problem is typically evaluated using a 
confusion matrix. There are several numbers of well-known accuracy measures for a two-class classifier 
in the literature. In this work, several scores extracted from the confusion matrix are presented: TP/FP 
rates (where TP is the number of true positives and FP is the number of false positives), Precision and 
AUROC values, for both training and validation processes. In the studies performed by Ferri et al., 
2009 and Huang and Ling, 2005 it was suggested that, in general, AUROC was the best measure for 
model comparison. Several experiments were performed in order to select the best models and the 
classification implementations used in those tests were the ones included in Weka. 
3.1. Artificial Neural Networks 
Artificial Neural Networks (Baxt, 1995, Bishop, 1995, Haykin, 1998 and Krogh, 2008) are flexible, 
non-linear and multidimensional mathematical systems, easily implemented and handled, capable of 
solving complex functions in very diverse fields. This technique is based on the simulation of the human 
cognition process (McCulloch & Pitts, 1943). ANNs have been widely used for different problems, such 
as data analysis, non-invasive diagnosis in the medical field (Ding et al., 2014 and Resino et al., 2011), 
linking chemical knowledge (Gomez-Carracedo et al., 2007 and Gómez-Carracedo et al., 2007) to protein 
function prediction (Fernandez-Lozano et al., 2013, Fernandez-Lozano et al., 2014 and Fernandez-
Lozano et al., 2014) or, as mentioned before, for AD classification with morphometric measures (Aguilar 
et al., 2013 and Escudero et al., 2011). ANNs consist of many simple, interconnected computational units. 
The knowledge lies in the connections links (weights) between these simple units (neurons). ANNs learn 
by example and have to be trained to adjust the weights which address the pattern recognition problem. 
After the training process, ANNs can assign labels to unknown data (not used in the learning process). 
The simplest kind of feed-forward ANN, where the inputs are directly connected to the outputs with a 
weight value, is known as single-layer perceptron or perceptron. If the problem is linearly separable, the 
single-layer perceptron learning algorithm will terminate. 
A multilayer perceptron (MLP) is a feed-forward neural network for non-linearly separable problems 
with three layers of neurons (input, hidden and output layer) fully connected to the next one with a non-
linear activation function. The MLP training process is performed by means of a back propagation 
technique in a supervised learning scheme. The election of a good topology is essential; therefore, most of 
the problems related to the development of the use of ANN are focused on it. There is no rule to choose 
the best topology to solve a particular problem, thus different topologies should be tested in order to 
obtain a final one. This search of topology could be done manually or automatically with other 
techniques, such as genetic algorithms (Holland, 1975 and Picado et al., 2009) or particle swarm 
optimisation (Fernandez-Lozano, Seoane, Gestal, Gaunt, & Campbell, 2013). 
  
3.2. Feature selection 
Feature selection (FS) is a helpful stage prior to classification, for dimensionality reduction, as well as 
selecting proper features and omitting improper features. The aim of feature selection is to select a subset 
of extracted variables in order to reduce the number of input variables for the classifier, since the number 
and relevance of the input variables can affect the performance of the model. An FS approach was 
performed to find the subset of features best describing the structure of the data. The FS process can 
answer the main question of how many and which are the most important features to discriminate 
between Alzheimer dementia and healthy control subjects. 
In this kind of problems, it is common to perform an FS approach in order to improve the performance 
of the classification and to choose the best features, solving the classification problem. There are mainly 
three approaches for FS (Saeys, Inza, & Larrañaga, 2007): Filter, Wrapper and Embedded. For the current 
study, a Filter approach was used to assess the relevance of features by looking only at the intrinsic 
properties of the data as a fast and simple computationally approach, independent of the particular 
classification algorithm. Fig. 2 presents the flow chart of the methodology used in this study: the 22 
attributes described above were retrieved for each subject from the full dataset (healthy controls, MCI and 
AD) using the three 
1
H-MRS studies. Finally, the best classification model was implemented as a free 
Web tool entitled “Alzheimer Prediction by Spectroscopy Voxel Volume” (AlzPred-SVV) at http://bio-
aims.udc.es/AlzPredSVV.php. The tool is based on an HTML/PHP user interface with a Python/Java 
implementation of the model. 
 
 
 
Fig. 2. Flow chart for the calculation of Alzheimer’s disease patient 
classification using 1H-MRS data and Weka machine-learning techniques and 
the implementation of the best model as a free Web tool for the prediction of 
Alzheimer’s.  
4. Results 
In the first step, the information of the 4 classes was used to look for classification results between Alz 
class (aMCI, mMCI and AD) and Control class, including the 3 pathological classes into a single group 
(Alz). Table 2 shows these results for each brain region with the following scores for the best models: 
TP/FP rates, Precision and AUROC values for both training and validation datasets, and the last two 
columns with the number and name of the features. Note that the best results were achieved in the left 
hippocampus (LH), followed by the right hippocampus (RH) and the parietal lobe (PL). The best model 
in the left hippocampus was a Naïve Bayes using estimator classes (John & Langley, 1995) with an 
AUROC value of 0.783. In the right hippocampus and parietal lobe, the best model was a multilayer 
perceptron (MLP) with AUROC values of 0.771 and 0.760. 
Table 2. Alz (mMCI, aMCI, AD) vs. control classification. 
Brain 
region 
Model 
Training  Validation 
No. of 
features 
Features 
TPR FPR Prec AUROC  TPR FPR Prec AUROC 
             
LH NaiveBayes 0.714 0.29 0.726 0.791  0.718 0.287 0.729 0.783 2 CSFvol/Tvol, GMvol/Tvol 
MLP H3:3 0.876 0.127 0.879 0.872  0.753 0.238 0.768 0.773 23 Pool 
BFTree 0.795 0.216 0.799 0.798  0.776 0.244 0.778 0.753 23 Pool 
MLP H3:1 0.861 0.148 0.862 0.843  0.722 0.277 0.736 0.752 23 Pool 
MLP 
H2:2:2 
0.853 0.157 0.855 0.842  0.734 0.266 0.746 0.751 23 Pool 
  
RH MLP H2:2 0.802 0.202 0.806 0.801  0.764 0.244 0.768 0.771 5 mI_Area, Tvol, GMvol, WMvol, 
CSFvol 
MLP 
H2:2:2 
0.814 0.183 0.82 0.802  0.752 0.259 0.755 0.769 7 mI_Conc, mI_Ampl, mI_Area, Tvol, 
GMvol, WMvol, CSFvol 
  
PL MLP H2:1 0.824 0.168 0.832 0.826  0.739 0.271 0.742 0.76 23 Pool 
FT 0.776 0.23 0.779 0.773  0.727 0.28 0.732 0.75 8 mI_Conc, Cho_Area, Cre_Ampl, 
NAA_Ampl, Tvol, GMvol, WMvol, 
CSFvol 
MLP H1:4 0.796 0.2 0.803 0.81  0.731 0.264 0.741 0.745 9 mI_Conc, Cho_Area, Cre_Conc, 
Cre_Ampl, NAA_Ampl, Tvol, 
GMvol, WMvol, CSFvol 
             
 
Table 3 presents the results obtained from mMCI vs. Control classification for each brain region. 
Again, the best AUROC values are obtained in the left hippocampus, but in this case using more features 
than in the right hippocampus and parietal lobe. Models with AUROC values lower than 0.74 are not 
presented in this work. This is the reason why there is no table for aMCI vs. Control classification (no 
significant results have been found). In this particular classification problem, for each brain region the 
best model found was an MLP with a different number of hidden layers, features and AUROC values of 
0.784, 0.754 and 0.764. 
  
Table 3. mMCI vs. control classification. 
Brain 
region 
Model 
Training 
 
Validation 
No. of 
features 
Features 
TPR FPR Prec AUROC 
 
TPR FPR Prec AUROC 
             
LH MLP 
H1:1:2 
0.867 0.181 0.866 0.834  0.818 0.24 0.818 0.784 9 ml_Conc, Cho_Area, Cre_Conc, 
Cre_Ampl, NAA_Ampl, Tvol, GMvol, 
WMvol, CSFvol, 
MLP 
H3:3 
0.909 0.114 0.910 0.880  0.776 0.259 0.786 0.775 10 mI/Cr, Cho_Conc, Cho/Cr, 
NAA_Conc,NAA/Cr, mI/NAA, Tvol, 
GMvol, WMvol, CSFvol, 
  
RH MLP 
H2 
0.796 0.213 0.815 0.817  0.766 0.267 0.782 0.754 5 mI_Conc, ml_Area, NAA_Conc, 
ml/NAA, Tvol 
MLP 
H1:5 
0.847 0.205 0.848 0.827  0.759 0.271 0.778 0.751 8 Tvol, GMvol, WMvol, CSFvol, ml/Cr, 
Cho/Cr, NAA/Cr, ml/NAA 
  
PL MLP 
H5:1 
0.874 0.152 0.882 0.854  0.778 0.258 0.802 0.764 5 mI_Area, Tvol, GMvol, WMvol, 
CSFvol 
MLP 
H4:1 
0.911 0.103 0.916 0.874  0.778 0.258 0.802 0.758 6 mI_Ampl, mI_Area, Tvol, GMvol, 
WMvol, CSFvol 
             
 
The next step consists of finding the most relevant features to discriminate patients affected by 
Alzheimer’s Disease. A feature selection had been performed for AD vs. Control classification (Table 4) 
and for MCI (aMCI, mMCI) vs. Control classification (Table 5). The models calculated for AD vs. 
Control classification presented good results, mainly in the left hippocampus with AUROC values higher 
than 0.89 (see Table 4). In the left and right hippocampus forest-based models achieved the best results. 
The best model in the parietal lobe was also an MLP with an AUROC value of 0.839. The aMCI and 
mMCI groups (Table 5) were joined together because, due to the heterogeneity of MCI, better results 
might be obtained by grouping all MCI diagnoses into one group. No significant results for the right 
hippocampus and parietal lobe were found, and the best model in the left hippocampus was a functional 
tree (Gama, 2004 and Landwehr et al., 2005) with a value of 0.805.  
Table 4. Feature selection for AD vs. control classification. 
Brain 
region 
Weka 
classifier 
Training 
 
Validation 
No. of 
features 
Features 
TPR FPR Prec AUROC 
 
TPR FPR Prec AUROC 
             
LH RotationForest 0.964 0.03 0.965 0.996  0.861 0.143 0.862 0.905 10 ml/Cr, Cho_Conc, Cho/Cr, 
NAA_Conc, NAA/Cr, ml/NAA, 
Tvol, GMvol, WMvol, CSFvol 
LogitBoost 0.903 0.095 0.905 0.951  0.818 0.181 0.822 0.894 7 ml_Conc, ml_Altura, ml_Area, 
Tvol, GMvol, WMvol, CSFvol 
MLP H2:2 0.867 0.129 0.870 0.902  0.836 0.150 0.846 0.890 3 Tvol, GMvol, WMvol 
  
RH RandomForest 0.994 0.004 0.994 1  0.795 0.203 0.803 0.859 8 mI_Conc, ml_Altura, ml_Area, 
Cho_Area, Tvol, GMvol, WMvol, 
CSFvol 
NaiveBayes 0.821 0.218 0.819 0.874  0.808 0.226 0.806 0.839 8 ml/Cr, Cho/Cr, NAA/Cr, ml/NAA, 
Tvol, GMvol, WMvol, CSFvol 
MLP H5:1 0.949 0.051 0.949 0.935  0.788 0.195 0.805 0.825 8 ml/Cr, Cho/Cr, NAA/Cr, ml/NAA, 
Tvol, GMvol, WMvol, CSFvol 
  
PL MLP H0 0.819 0.187 0.823 0.876  0.781 0.242 0.782 0.839 8 ml_Conc, Cho_Area, Cre_Ampl, 
NAA_Ampl, Tvol, GMvol, WMvol, 
CSFvol 
FT 0.831 0.154 0.843 0.838  0.794 0.203 0.803 0.831 8 ml_Conc, Cho_Area, Cre_Ampl, 
NAA_Ampl, Tvol, GMvol, WMvol, 
CSFvol 
MLP H3:3 0.869 0.112 0.88 0.885  0.769 0.249 0.771 0.818 9 ml_Conc, Cho_Area, Cre_Conc, 
Cre_Ampl, NAA_Ampl, Tvol, 
GMvol, WMvol, CSFvol 
 
Table 5. Feature selection for MCI (aMCI, mMCI) vs. control classification. 
Brain 
Region 
Weka 
classifier 
Training 
 
Validation 
No. of 
features 
Features 
TPR FPR Prec AUROC 
 
TPR FPR Prec AUROC 
             
LH FT 0.708 0.291 0.709 0.73  0.781 0.219 0.781 0.805 3 GMvol, CSFvol, 
GMvol/Tvol 
DTNB 0.719 0.281 0.719 0.708  0.745 0.254 0.746 0.782 4 Tvol, GMvol, WMvol, 
CSFvol 
JRip 0.724 0.276 0.724 0.704  0.76 0.241 0.761 0.775 3 Tvol, GMvol, CSFvol 
             
 
Finally, Table 6 summarises the best Alzheimer classification models for each brain region based on a 
maximum of only two features. Therefore, the best Alzheimer model in this study was obtained for the 
AD vs. Control classification, with the MLP H0 classifier, a linear classifier with no hidden layers that 
represents a single-layer perceptron (AUROC = 0.866), based on only two variables related to the 
spectroscopic voxel volumes: Tvol and CSFvol, in the left hippocampus. 
  
Table 6. The best models based on two features. 
Classification 
Brain 
region 
Weka 
classifier 
Training  Validation 
No. of 
features 
Features 
TPR FPR Prec AUROC  TPR FPR Prec AUROC 
              
AD vs. 
Control 
RH LADTree 0.853 0.111 0.877 0.934  0.737 0.271 0.745 0.788 2 Tvol, CSFvol 
LH MLP H0 0.83 0.187 0.83 0.875  0.812 0.204 0.812 0.866 2 Tvol, CSFvol 
LMT 0.824 0.172 0.829 0.886  0.794 0.212 0.797 0.855 2 Tvol, GMvol 
Kstar 0.903 0.114 0.903 0.976  0.794 0.235 0.793 0.846 2 Tvol, CSFvol 
  
Alz vs. 
Control 
LH NaiveBayes 0.734 0.278 0.741 0.794  0.737 0.276 0.744 0.784 1 CSFvol/Vol_tot 
              
 
5. Discussion 
The current work presents for the first time the use of machine-learning methods on 
1
H-MRS data for 
AD classification. A gender-matched cohort of 260 subjects aged between 57 and 99 years was used to 
obtain the attribute values for our datasets. 
The best proposed model to directly predict the AD diagnostic is based on only two variables related 
to the spectroscopic voxel volumes such as Tvol and CSFvol in the left hippocampus, and a well-known 
single-layer perceptron. These results are in accordance with previously published works in different 
fields, indicating that ANN approaches provide higher prediction accuracy for solving classification 
problems (Mazurowski et al., 2008). All the models were tested using a cross-validation approach. This 
work demonstrates a robust predictor of AD with an AUROC value of 0.866 and only two features, 
according to the TPR and FPR values (0.812 and 0.204) achieved in validation and the optimal precision 
value. This result supports the hypothesis that a single-layer perceptron can predict AD if applied to an 
unknown dataset. The results also confirm that a single-layer perceptron is an accurate method for the 
detection of AD. In general, ANNs are potentially a more successful technique than other previously 
published traditional statistical approaches, when used for predicting the stage of a complex biological 
process (Almeida, 2002). 
These good results obtained for the left hippocampus match with the neuropathologic concept of 
evolution of AD according to the Braak and Braak staging (Braak & Braak, 1991). Atrophy typically 
starts in the medial temporal and limbic areas, subsequently spreading to parietal association areas and 
finally to frontal and primary cortices. This interpretation is further supported by accumulating 
morphometric evidence in MCI and AD patients, proposing hippocampal atrophy as a predictor of 
subsequent conversion to AD and to discriminate control subjects from AD patients (Ackl et al., 
2005 and Dubois et al., 2007). Early changes in hippocampi have been demonstrated with the help of 
MRI, mainly in the left temporal lobe. As expected, the best results and the AUROC values with higher 
accuracy are obtained discriminating between AD patients and healthy controls, the two most distant 
groups. As shown in the results section, MLP seems to achieve good results also for the right 
hippocampus and parietal lobe. 
The lack of significant results for the classification of Control and aMCI subjects could be due to the 
diverse etiology of MCI. Although MCI is a category at high risk of developing dementia, it is becoming 
progressively evident that under this definition, there is a heterogeneous group of cognitive decline 
having different outcomes. Some MCI patients never develop dementia and not all AD patients pass 
through MCI stage. For the same reason, the classification of Control and Alz group has lower accuracy 
than Control vs. AD. The high heterogeneity of the Alz group with respect to cause and severity of the 
disease (it includes patients diagnosed with aMCI, mMCI and AD), may reduce the classification success 
rate and thereby could affect the consistency of the results. 
The analysis of 
1
H-MRS data showed that all studied metabolites are relevant for the classification 
process. By relevance, mI could be mentioned first, since it appears in most of the feature selections, 
followed by NAA and Cho. These results are in accordance with the literature. As mentioned above, there 
have been reports of increased mI in subjects with MCI and AD, which is suggestive of an increase in 
glial content or membrane abnormality in these pathologies. (Parnetti et al., 1997) reported that the 
increase of mI was correlated with dementia severity and duration. Moreover, several studies reported a 
decrease of NAA values in AD patients and the values achieved for MCI subjects were in between that of 
healthy subjects and AD patients (Catani et al., 2001 and Kantarci et al., 2000). The results obtained by 
Tumati et al. (2013) also showed decreases in NAA levels in the posterior cingulate and hippocampus in 
both the ratio and concentration values. These findings support the role of reduced NAA as a biomarker 
for the diagnosis of MCI and AD. Although in the results of the current study Cho values seem an 
important feature to discriminate between groups, the findings in the literature with respect to Cho in MCI 
and AD subjects were less consistent. The alterations of membrane biochemistry accompanying AD have 
profound effects on the concentration of various choline-containing compounds. Some studies reported an 
increase in Cho levels in grey matter (Kantarci et al., 2000 and Pfefferbaum et al., 1999). This increase 
was associated with decreased memory function (Pfefferbaum et al., 1999) and decreased regional 
cerebral metabolism (Mielke et al., 2001). However, other studies reported no significant changes in the 
Cho in subjects with AD (Frederick et al., 1997 and Huang et al., 2001). 
Note that not only metabolite concentrations had significant results. Ratios with Creatine, mI/Cr, 
NAA/Cr and Cho/Cr, are shown as selected features in several classifications (see Table 2, Table 
3 and Table 4). In some cases, ratios between metabolites are more sensitive in terms of detecting changes 
(ex. when a metabolite increases and other decreases) and can be more accurate than absolute 
concentrations. Other than Cr ratios, mI/NAA should be pointed out as another selected feature. 
Combining the alterations in NAA and mI levels in AD, it was suggested that mI/NAA ratios may 
provide a basis for a 
1
H-MRS diagnostic assay (Doraiswamy et al., 1998 and Shonk et al., 1995). The 
study performed by Wang, Zhao, Yu, Zhou, and Li (2009) revealed significant elevation of mI/NAA ratio 
in the hippocampus and a significant correlation was found between mI/NAA ratio and cognitive decline. 
In addition to the concentration and ratios, the metabolite measurements of peak amplitude and area are 
also relevant to discriminate between groups. The importance of this result is that these measures are not 
routinely used to quantify spectra, although the area under a metabolite curve in 
1
H-MRS is directly 
proportional to the concentration of the metabolite. 
In the current work, besides the 
1
H-MRS data, the volumes of GM, WM and CSF have been used 
within the spectroscopic voxel to consider the problem of variations in tissue composition caused by 
neurodegeneration. They could affect the variability and the metabolite concentrations. The results 
obtained for the different tissue volumes of the voxel are very significant (see Table 5 and Table 6). They 
suggest that just the voxel prescription and the relative proportions of tissue provide a high correlation 
with the diagnosed groups. Due to the tissue atrophy in MCI and AD pathologies, the brain loses grey and 
white matter and, as a result, increases the cerebrospinal fluid. This fact is observed by these results 
showing a strong potential for discriminating between controls, MCI and AD subjects, mainly by the 
increase of CSF within the voxel with the progression of the disease. The voxel volume variables show 
more power than metabolites to discriminate between groups, since only two features are required for 
classifications over 70% (see Table 6). 
The current results are based on the application for the first time of 
1
H-MRS data and machine-
learning techniques to the classification of AD. Therefore, the results are not easily comparable with 
previous studies. Besides, the comparison with other studies that have been performed with MRI 
anatomical data is difficult because they report a range of different accuracies for classification and 
prediction tasks and they have used different cohorts, features, and techniques. The classification 
accuracy could be influenced by several factors including both methods and cohort properties: feature 
extraction methods, feature selection or classification tools, image quality, number of subjects, 
demographics and clinical diagnosis criteria are also important considerations. Only a few large 
multicenter cohorts are available in the field of AD. The Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) is the most commonly used cohort (ADNI, 2015). ADNI is a North American-based study that 
was launched in 2003 and aimed to recruit 800 adults (approximately 200 cognitively normal older 
individuals, 400 people with MCI, and 200 people with early AD) to participate in the research and be 
followed for 2–3 years. ADNI subjects were aged between 55 and 90, and were recruited from over 50 
sites across the US and Canada. Many of the recent studies in the field have used this cohort to benefit the 
comparison between studies. However, ADNI or any other public database has no data from 
1
H-MRS 
studies, as using these public datasets for this study or any other study about spectroscopy was not 
possible. Almost all studies published in the literature about 
1
H-MRS use their own sample data. 
Despite all this, the scores obtained with spectroscopic data to classify AD patients and cognitively 
normal subjects are in agreement with previous studies that use MRI data. The classification accuracy for 
distinguishing between AD subjects and Control individuals tends to be between 80% and 90%. The 
accuracies are rarely higher for studies using large sample sizes. Studies achieving close to 100% 
accuracies are likely to have an over-fitted model, resulting from very small homogenous samples or they 
may use clinical measures for diagnosing the subjects as input, leading to circularity problems (Falahati et 
al., 2014).  
The study carried out by Aguilar et al. (2013) compared different multivariate classifiers using MRI 
data as input for classification of AD vs. Controls out of a total of 345 subjects: 116 AD, 119 MCI and 
110 Controls. Similar performance was obtained for the different methods: DT (accuracy = 81.9% and 
AUROC = 0.78), ANN (accuracy = 84.9% and AUC = 0.88) and SVM (accuracy = 83.6% and 
AUROC = 0.91). The classification performance was based on 10-fold cross-validation for each 
classifier, leading to the same input; using the same cohort, different multivariate classifiers tend to 
perform very similarly. Using SVM, (Abdulkadir et al., 2011) reported an accuracy of 87% for an MRI 
dataset comprising 417 subjects from the ADNI database, while (Cuingnet et al., 2011) obtained 81% 
sensitivity and 95% specificity for MRI data from 299 subjects from the same database. 
The study conducted by Di Deco et al. (2013), with a subset of the cohort used for this study, 
employed combinations of different MR neuroimaging biomarkers, including 
1
H-MRS metabolites, to 
classify AD in its different stages. Regarding the spectroscopic data, they reported accuracies of 74% for 
discriminating between controls and aMCI, which are similar to the results of the current study, and 77% 
for discriminating between controls and AD, where the current study presents better accuracies (higher 
than 85%). 
6. Conclusion 
The number of features plays an important role in a classification problem. It is necessary to study the 
relevance in order to suppress noise by means of a feature selection approach. It is known that a model 
with a high number of features could suffer from over-fitting (Hastie, Tibshirani, & Friedman, 2009) and 
the current study also looked for a smaller subset with better accuracy results in order to get a better 
interpretation of the results. Those approaches are applied in order to improve the classification accuracy 
and to enhance the interpretability of the results. In this work, a single-layer perceptron outperforms the 
results achieved with other machine-learning techniques included in the Weka algorithms collection and it 
seems to be more suitable for describing this complex biological system. 
In conclusion, our study reflects that the best classifier in terms of AUROC is a single-layer 
perceptron with only two spectroscopic voxel volumes (Tvol and CSFvol) in the left hippocampus, with 
an AUROC value of 0.866 (with TPR 0.812 and FPR 0.204). The scores obtained are in accordance with 
previous studies in AD classification (ranging from 80% to 90%). Our results suggest that precise 
composition of white and grey matter and cerebrospinal fluid is essential in a 
1
H-MRS study to improve 
the accuracy of the quantifications and classifications, particularly in those studies involving elder 
patients and neurodegenerative diseases. However, further investigation involving larger patient cohorts 
are needed to increase confidence and reproducibility of these methods. 
As mentioned before, there are different approaches for AD prediction using different types of data. 
Future research using MRI data, different MR Neuroimaging biomarkers and a combination with some 
genomic data for clinical tests could be performed following a data fusion scheme (Lanckriet, De Bie, 
Cristianini, Jordan, & Noble, 2004). One of the main drawbacks of ANN approaches is precisely the 
impossibility to calculate the real contribution of each feature in the final solution whilst this could be 
calculated following the aforementioned data fusion approach (Seoane, Day, Gaunt, & Campbell, 2013). 
The best model was implemented as Alzheimer Prediction by Spectroscopy Voxel Volume (AlzPred-
SVV) at http://bio-aims.udc.es/AlzPredSVV.php, an easy-to-use web application to validate our model. 
Such development can be useful for both clinicians and patients. This application is on a free portal that 
offers theoretical models based on Artificial Intelligence, Computational Biology and Bioinformatics to 
study complex systems, with the goal of having the largest possible dissemination. The website provides 
the values of predicted class and error prediction achieved by the model. 
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